Recently, SENSORO, an IoT and artificial intelligence unicorn company from China, announced the release of a new ESG solution brand named "SENSORO SOLUTION". The program aims at climate monitoring, ecological protection, livelihood improvement, animal welfare, garbage classification and other applications. Its smart city benchmark case has been built in Yichang, Hubei Province. SENSORO is relying on its independent research and development capabilities in the AIoT field to implement the modern service concept of sustainable development, which contributes to the digital and intelligent development of China's urban and rural areas.
Technology Rooted in Reality with Multiple Values
As a city-level data technology service provider, SENSORO has received repeated attention from the capital market, and also attracted many research scholars, doctors, and other talents to join. Through independent research and development, the team has created an end-to-end, integrated IoT and AI technology and product system, including smart sensing terminals, IoT communication base stations, chips and edge computing servers, and a global data visualisation service platform.
SENSORO ESG smart solutions have been implemented on a large scale in Yichang, Hubei Province. It has played a role in many areas, including COVID-19 pandemic prevention and control, weather monitoring and early warning, Yangtze River ecological protection, care for vulnerable groups, grassroot-level inclusive medical care, animal welfare protection, garbage classification. SENSORO is harnessing the power of the Internet of Things and artificial intelligence to direct urban construction towards a new stage of low-carbon, energy-saving, high-efficiency and intelligence, using revolutionary smart data solutions to add vigor and vitality to traditional industries and economic development.
Technological Innovation Services for Real
Technology is people-oriented. Dazhong Tao, a local resident in Yichang, Hubei Province, where SENSORO's digital service is located, was deeply moved. He said, "These high technologies have provided us with enormous convenience in our everyday life, making our lives more secure. For example, we can easily access health service."
SENSORO CEO Tony Zhao also said,"Our hope is to use ESG as a guide to offer more digital solutions for the environment, society and governance. We are willing to work with partners in various industries to build a more environmentally friendly, safer, livable and smart city. Furthermore, we have already witness such changes taking place now. Changes will continue to happen in the future."
Pantum, a brand that develops, manufactures, and sells laser printers and toner cartridges for users around the world, is celebrating its 11th anniversary this December, marking more than a decade of unwavering product optimization and innovation. Over the past 11 years, the company has built up a comprehensive product portfolio of single-function, multi-function, monochromatic, color, A4 and A3 printers. During this time, it has also expanded its sales network to cover 80 countries and regions around the world, with the aim of providing global users with exceptional, efficient products and services.
This year, Pantum launched the all-new Elite Series, and with A4 printing speeds of up to 40 pages per minute (PPM), it is the company's fastest model yet. The Elite Series, which includes BP5100 Series (BP5100DN/BP5100DW) and BM5100 Series (BM5100ADN/BM5100ADW, BM5100FDN/BM5100FDW), can substantially assist in resolving the daily challenges including slow printing speeds and time-consuming waiting. In addition to the 250-page standard tray and the 60-page multi-function tray, two additional 550-page large-capacity trays will increase the maximum feed capacity to 1410 pages. It is targeted to the needs of a wide range of commercial customers, from SMEs and governments to large institutions, with more convenient features such as one-step driver installation and automatic duplex printing. One-step driver installation can aid in the intelligent identification of printer connection methods such as USB, network, or Wi-Fi connection. Automatic duplex printing allows users to save 50% of their paper usage and reduce 50% of their expenditure.
As the pandemic persisted, the company also promoted the more "speedy, stable, smart, and simple" 4S Efficiency series to provide economical printing solutions. Pantum is constantly modifying to improve the user experience for SMB users by observing and researching workplace environments and habits. Focusing on the ease of daily use and long-term savings, Pantum has identified and improved printer features that benefit SMBs the most. The printing speed and paper input are optimized for SMB users that print small to medium volumes of documents and do not need to refill input paper tray frequently. Also aimed at remote work, it is the perfect pandemic companion thanks to features such as mobile printing.
In 2021, Pantum is committed to continuously improving its product line. Pantum 's Elite Series not only filled the higher-end sector of the company's offering, but also gave customers more options to suit their various needs. As the world looks to 2022, Pantum will continue to channel its efforts into optimizing its printer products and services, so as to provide users around the world with more diverse product choices and convenient user experience.
For more information, please visit our website, Facebook, Instagram, and YouTube.
For any media inquiries, please contact: Pantum, info@pantum.com.
The term 'NFT' has been elected word of the year 2021 (all languages combined) by the Collins English Dictionary. The blockchain technology supporting the existence of NFTs was officially born in 2017, but it is only in the last ten months that it has attracted the general public's attention by inviting itself into the art auction sphere. Today, it seems everyone is talking about NFTs…
This new digital market could merge completely with the physical art market; it already represents 8% of global secondary art market auction turnover. However, the two universes might also develop in parallel, with brief forays into each other's territory, the physical world on one side and the metaverse on the other… like Ying and Yang.
thierry Ehrmann, CEO and Founder of Artmarket.com and its Artprice department: "The appearance of NFTs in the auction sphere represents a genuine revolution, the intensity of which can be explained both by long bottled-up demand and a particularly favorable economic context. Beeple's initial record ($69.3 million) back in March perfectly illustrates this pent-up demand, the scale of which Christie's itself had not predicted. NFTs question the art market's traditional modus operandi, since artists without any market history (but with a huge community on social networks) can, in a few hours, reach prices usually reserved for the likes of Rene Magritte and Willem de Kooning".
Artprice by Artmarket.com explains the NFTs for 2022
Artmarket.com: Perfectly Positioned to Generate Enormous Revenue From Its NFT Marketplace on Artprice-nft.com
Artmarket.com: Artprice Manifesto - The future of NFTs and the Metaverse
Artmarket.com: Here's why the art market, via the NFT revolution, will enjoy exponential growth with Artprice
Artprice looks back at the key developments of the year 2021, quarter by quarter.
Q1: Boticelli vs. Beeple
Unveiled in September 2020, just before a second global wave of the Covid pandemic, Portrait of a Young Man Holding a Roundel (attributed to the Florentine painter Sandro Botticelli) was put up for sale by Sotheby's in New York on 28 January 2021. Despite doubts surrounding the attribution of the world's most expensive artwork (Salvator Mundi) to Leonardo da Vinci, and despite a still uncontrollable pandemic, this rare Botticelli masterpiece sold for $92 million, the second highest auction result of all time for a work by an Old Master.
However the biggest surprise of the year came on 11 March 2021 when Christie's online auction platform sold what looked at first glance like a simple jpeg… for $69.4 million. The artist behind the work, Beeple, was totally unknown to the art market, but he had millions of followers on Instagram who know the 5,000 digital works offered by Christie's in the form of an NFT. Faced with the unexpected enthusiasm of new bidders, Francois Pinault's prestigious auction house accepted payment in a cryptocurrency for the first time in its history.
Q2: A flurry of records in the spring
It took a few months for the art market to fully appreciate the nature and implications of non-fungible tokens. During April 2021, two other major auction houses are also launched the sale of NFTs: Sotheby's with The Fungible Collection by Pak, and Phillips with the work Replicator by Mad Dog Jones. The prices obtained for these works continued to disconcert collectors and analysts.
Fortunately in May 2021, New York's traditional major art sales resumed, and a very physical artwork crossed the $100 million threshold for the first time in two years. Woman Seated Near a Window (Marie-Therese) (1932) by Pablo Picasso was acquired for $103 million at Christie's on 13 May 2021. In its wake, almost all of the art market's major signatures fetched very reassuring prices: Basquiat, Monet, Van Gogh, Warhol,… with lots of artists revising their personal auction records.
Top 5 new artist records recorded in May 2021 in New York
Richard Diebenkorn: Ocean Park # 40 (1971) - $27,265,500 - 12/05/2021, Sotheby's
Barbara Hepworth: Parent II (1970) - $7,110,000 - 13/05/2021, Christie's
Q3: Online sales didn't stop during the summer
Traditionally, the major auction houses have always taken a break from sales during the months of July and August, in conjunction with the closure of art galleries and art fairs. But in 2020, the postponements caused by the covid pandemic and the establishment of new online sales platforms encouraged auction houses to continue part of their activities throughout the summer period, an exercise that was repeated in 2021, with online sales ensuring the circulation of works to all four corners of the globe.
A total of 121,000 fine art lots were auctioned in the third quarter of 2021. This historic transaction intensity for the summer period was largely driven by the Asian market; not just by sessions in Hong Kong, but also in mainland China, South Korea and Japan.
Top 3 Fine Art results in Asia during July and August 2021
Fu Baoshi (1904-1965): Spring (1963) - $4,400,000 - 25/07/2021, Xiling Yinshe Hangzhou
Whan-Ki Kim (1913-1974): 1 -VII 71 # 207 (1971) - $4,152,720 - 24/08/2021, Seoul Auction
Q4: All indicators turn green…
The months of October and November saw countless new records for all creative periods: Jackson Pollock, Gustave Caillebotte, Peter Doig, Frida Kahlo, Banksy, Pierre Soulages, Agnes Martin, etc. The sales of two very prestigious American collections - the Impressionist Cox Collection at Christie's, and the Post-War Macklowe Collection at Sotheby's - made the last quarter of 2021 the most prosperous Q4 in American art market history.
Expected to rebound after a 2020 marked by the Covid-19 pandemic, Artprice will be looking more closely at this highly positive turn of events in its upcoming Annual Art Market Report.
Aside from the NFT phenomenon, one of the year's key trends was the emergence of the Hong Kong market which proved to be absolutely decisive for the global art market as a whole. Not only did it host sales, for the first time, of major works by Jean-Michel Basquiat in Asia, it also hammered new records for major signatures, both Western (Richard Prince) and Asian (Yayoi Kusama). But, above all, Hong Kong emerged as the new hub for red chip artists - i.e. young signatures who trigger passionate bidding - like the American artist Avery Singer and the Ghanaian artist Amaoko Boafo. Last, but not least… Hong Kong is also emerging as one of the major new capitals for NFT sales.
Subscribe to our services: https://www.artprice.com/subscription
About Artmarket:
Artmarket.com is listed on Eurolist by Euronext Paris, SRD long only and Euroclear: 7478 - Bloomberg: PRC - Reuters: ARTF.
Discover Artmarket and its Artprice department on video: www.artprice.com/video
Artmarket and its Artprice department was founded in 1997 by its CEO, thierry Ehrmann. Artmarket and its Artprice department is controlled by Groupe Serveur, created in 1987.
See certified biography in Who's who (C): Biographie_thierry_Ehrmann_2022_WhosWhoInFrance.pdf
Artmarket is a global player in the Art Market with, among other structures, its Artprice department, world leader in the accumulation, management and exploitation of historical and current art market information in databanks containing over 30 million indices and auction results, covering more than 770,000 artists.
Artprice by Artmarket, the world leader in information on the art market, has set itself the ambition through its Global Standardized Marketplace to be the world's leading Fine Art NFT platform.
Artprice Images(R) allows unlimited access to the largest Art Market image bank in the world: no less than 180 million digital images of photographs or engraved reproductions of artworks from 1700 to the present day, commented by our art historians.
Artmarket with its Artprice department accumulates data on a permanent basis from 6300 Auction Houses and produces key Art Market information for the main press and media agencies (7,200 publications). Its 5.4 million ('members log in'+social media) users have access to ads posted by other members, a network that today represents the leading Global Standardized Marketplace(R) to buy and sell artworks at a fixed or bid price (auctions regulated by paragraphs 2 and 3 of Article L 321.3 of France's Commercial Code).
Artmarket with its Artprice department, has been awarded the State label "Innovative Company" by the Public Investment Bank (BPI) (for the second time in November 2018 for a new period of 3 years) which is supporting the company in its project to consolidate its position as a global player in the market art.
Artprice's 2020/21 Contemporary Art Market Report by Artmarket.com: https://www.artprice.com/artprice-reports/the-contemporary-art-market-report-2021
Artprice by Artmarket's 2020 Global Art Market Report published in March 2021: https://www.artprice.com/artprice-reports/the-art-market-in-2020
Index of press releases posted by Artmarket with its Artprice department: serveur.serveur.com/Press_Release/pressreleaseEN.htm
Follow all the Art Market news in real time with Artmarket and its Artprice department on Facebook and Twitter:
www.facebook.com/artpricedotcom/ (over 5,4 million followers)
twitter.com/artmarketdotcom
twitter.com/artpricedotcom
Discover the alchemy and universe of Artmarket and its artprice department https://www.artprice.com/video headquartered at the famous Organe Contemporary Art Museum "The Abode of Chaos" (dixit The New York Times): https://issuu.com/demeureduchaos/docs/demeureduchaos-abodeofchaos-opus-ix-1999-2013
L'Obs - The Museum of the Future: https://youtu.be/29LXBPJrs-o
Artmarket.com: Perfectly Positioned to Generate Enormous Revenue From Its NFT Marketplace on Artprice-nft.com (Artmarket.com มีสถานะที่ดีในการสร้างรายได้จำนวนมหาศาลจาก NFT Marketplace ใน Artprice-nft.com)
Artmarket.com: Artprice Manifesto - The future of NFTs and the Metaverse (Artmarket.com: Artprice Manifesto - อนาคตของ NFTs และเมตาเวิร์ส)
Artmarket.com: Here's why the art market, via the NFT revolution, will enjoy exponential growth with Artprice (Artmarket.com เผยเหตุผลที่ NFT จะผลักดันให้ตลาดงานศิลปะเติบโตอย่างทวีคูณบนแพลตฟอร์ม Artprice)
สำรวจการเล่นแร่แปรธาตุและจักรวาลของ Artmarket และฝ่าย Artprice https://www.artprice.com/video มีสำนักงานใหญ่ที่พิพิธภัณฑ์ศิลปะร่วมสมัยชื่อดัง Organe "The Abode of Chaos" (คำนิยม The New York Times): https://issuu.com/demeureduchaos/docs/demeureduchaos-abodeofchaos-opus-ix-1999-2013
L'Obs - The Museum of the Future: https://youtu.be/29LXBPJrs-o
The 23rd China High-Tech Fair (CHTF2021) opened in Shenzhen, China on December 27, 2021.
CHTF 2021 includes both online and offline components spanning five days and three days respectively. More than 1,900 domestic and foreign enterprises appeared on the first day of the CHTF's online exhibition, covering various high-tech fields such as the next generation of Internet and communications technology including cloud computing and 5G, and strategic emerging industries encompassing environmental protection, new energy vehicles, and aerospace.
Notable domestic corporate brands in attendance at this year's CHTF include Huawei, ZTE, Honor, and Changhong Group. They are joined by Tsinghua University, Peking University and other top academic institutions, while the Ministry of Commerce, the Ministry of Industry and Information Technology, and other government departments also set up exhibitions.
As an internationally renowned science and technology event, CHTF provides an important stage for sharing critical insights into new market needs, future technology, and new trends in industry development. This year's CHFT is focused on a number of prominent themes rooted in China but with global relevance, such as "New Era, New Economy", "Carbon Peaking and Carbon Neutrality", and "China's Smart Manufacturing". Popular buzzwords at the moment, such as the post-pandemic era and the metaverse, are firmly encapsulated by the hardcore scientific and technological innovation products and technologies on display at CHTF.
The international presence at CHTF 2021 is unique, with exchanges and cooperation between Chinese and foreign partners ongoing despite the global pandemic. Enterprises from 25 countries are displaying online, while delegations from 11 countries including Belgium, Brazil, Poland are exhibiting in person at Shenzhen World Exhibition and Convention Center.
An integral component of CHTF is the China High-Tech Forum, which has become an essential platform for sharing the latest scientific and technological developments, understanding both the Chinese and global economy, and strengthening international technical and economic cooperation. This year's forum will be attended by nearly 50 experts, scholars, and business representatives.
Virtual Exhibition and Online Forum: https://online.chtf.com/pcen23/#/Home
Official Website: https://www.chtf.com/english/ Facebook: @CHTFChina LinkedIn: @China Hi-tech Fair
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, today announced that the Drugs Controller General of India (DCGI) has granted emergency use authorization (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M(TM) adjuvant. The vaccine will be manufactured and marketed in India by SII under the brand name Covovax(TM).
"No one is safe until everyone is safe, and today's authorization marks a vital step for India, where additional vaccine options and millions of doses are needed in the country's ongoing efforts to control the pandemic," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "Novavax and SII will not rest in our partnership to deliver our vaccine to those in India and across the globe, as we work to protect the health of people everywhere."
Because the vaccine is stored with standard refrigeration at 2? to 8? Celsius, it may be transported and stored using existing vaccine supply chain, potentially increasing access in hard-to-reach areas.
"The approval of Covovax in India marks a significant milestone in strengthening our immunization efforts across India and LMICs," said Adar Poonawalla, Chief Executive Officer, Serum Institute of India. "We are proud to deliver a protein-based COVID-19 vaccine, based on Phase 3 clinical data demonstrating more than 90% efficacy and a favorable safety profile, to our nation."
The Novavax/SII vaccine recently received EUA in Indonesia and the Philippines, as well as Emergency Use Listing (EUL) with the World Health Organization (WHO). Novavax was also granted Conditional Marketing Authorization by the European Commission and EUL with the WHO for its vaccine, which will be marketed by Novavax as NuvaxovidTM. Novavax has also announced regulatory filings for its vaccine in multiple countries worldwide, while partners SK bioscience and Takeda have submitted regulatory filings in South Korea and Japan, respectively. Novavax expects to submit the complete package to the U.S. FDA by the end of the year.
For additional information on Covovax, please visit the following websites in the coming days:
Central Drugs Standard Control Organization (India)
Serum Institute of India
Authorized Use of Novavax' Covid-19 Vaccine in India The Drugs Controller General of India (DCGI) has issued Emergency Use Authorization (EUA) for Covovax /Recombinant Spike Protein of SARS-CoV-2 Virus 5 mcg to induce immunity against SARS-CoV-2 to prevent COVID-19 for adults 18 years old and above.
Authorization in the U.S. NVX-CoV2373 has not yet been authorized for use in the U.S. and the trade name Nuvaxovid has not yet been approved by the U.S. FDA.
Important Safety Information Covovax is contraindicated in persons who have hypersensitivity to the active substance or to any of the excipients of this vaccine.
About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M(TM) adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
Novavax' COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2?- 8? Celsius, enabling the use of existing vaccine supply and cold chain channels. The current assigned shelf-life of the vaccine is 9 months.
Novavax has established partnerships for the manufacture, commercialization and distribution of NVX-CoV2373 worldwide.
About the NVX-CoV2373 Phase 3 trials
NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials.
A trial conducted in the U.K. with 14,039 participants was designed as a randomized, placebo-controlled, observer-blinded study and achieved overall efficacy of 89.7%. The primary endpoint was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least 7 days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. Full results of the trial were published in the New England Journal of Medicine (NEJM).
PREVENT-19, a trial in the U.S. and Mexico, with 25,452 participants, achieved 90.4% efficacy overall. It was designed as a 2:1 randomized, placebo-controlled, observer-blinded study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373. The primary endpoint for PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least 7 days after the second dose in serologically negative (to SARS-CoV-2) adult participants at baseline. The statistical success criterion included a lower bound of 95% CI >30%. The key secondary endpoint is the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Both endpoints were assessed at least seven days after the second study vaccination in volunteers who had not been previously infected with SARS-CoV-2. It was generally well-tolerated and elicited a robust antibody response in both studies. Full results of the trial were published in NEJM.
About Matrix-M(TM) Adjuvant Novavax' patented saponin-based Matrix-M(TM) adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
About Novavax Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, received Conditional Marketing Authorization from the European Commission, Emergency Use Listing from the World Health Organization, Emergency Use Authorization in India, Indonesia and the Philippines, and has been submitted for regulatory authorization in multiple markets globally. NanoFlu(TM), the company's quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Novavax is currently evaluating a COVID-NanoFlu combination vaccine in a Phase 1/2 clinical trial, which combines the company's NVX-CoV2373 and NanoFlu vaccine candidates. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M(TM) adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter, LinkedIn, Instagram and Facebook.
About Serum Institute of India Pvt. Ltd. Driven by the philanthropic philosophy of affordable vaccines, Serum Institute of India Pvt, Ltd. is the world's largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses), supplying the world's least expensive and WHO-accredited vaccines to as many as 170 countries. It was founded in 1966 with the aim of manufacturing lifesaving immunobiological drugs including vaccines worldwide. With a strong commitment towards global health, the institute's objective has been proliferated by bringing down the prices of newer vaccines such as such as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. SII is credited with bringing world-class technology to India, through its state-of-the-art equipped multifunctional production facility in Manjari, Pune; association with Zipline and government agencies to transform emergency medicine and critical care along with spearheading the race of vaccine development against the COVID-19 pandemic.
Forward-Looking Statements Statements herein relating to the future of Novavax, its operating plans and prospects, the ongoing development of NVX-CoV2373 and its partnerships, the scope, timing and outcome of future regulatory filings and actions, the role that COVOVAX may play in helping to increase vaccination rates and to control the COVID-19 pandemic in India and across the globe, Novavax' and SII's continued efforts to deliver COVOVAX to those in India and across the globe, and COVOVAX's potential to increase vaccination access in hard-to-reach areas are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax' Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contacts:
Investors Novavax, Inc. Erika Schultz | 240-268-2022 ir@novavax.com
Solebury Trout Alexandra Roy | 617-221-9197 aroy@soleburytrout.com
Media Ali Chartan | 240-720-7804 Laura Keenan Lindsey | 202-709-7521 media@novavax.com
Serum Institute of India Mayank Sen | +919867974055 mayank.sen@seruminstitute.com
Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg
